How Does Tirzepatide Actually Work? The Dual-Hormone Mechanism, Explained

What does tirzepatide actually do in the body?

Tirzepatide is a dual agonist: one molecule built to switch on two hormone receptors instead of one. The two hormones are GLP-1, short for glucagon-like peptide-1, and GIP, short for glucose-dependent insulinotropic polypeptide. Your gut releases both after you eat. Both help your body handle food and blood sugar.

Semaglutide, the drug in Ozempic and Wegovy, targets only the GLP-1 receptor. Tirzepatide's structure lets it act on both at once. That is why it is sometimes called a twincretin.

The two receptors aren't activated equally. Tirzepatide binds the GIP receptor about as strongly as the natural hormone does. It binds the GLP-1 receptor more weakly than natural GLP-1. Researchers think the imbalance is deliberate. GLP-1 action drives most of the nausea, so leaning on GIP may help tirzepatide work strongly without as much of it.

In practice, the combined signal changes how your body handles a meal:

• Slower stomach emptying: food stays in the stomach longer, so you feel full for longer.
• Quieter hunger: it acts on appetite centers in the brain. For many people, that also quiets the constant mental chatter about food.
• Smarter insulin release: it triggers insulin only when blood sugar is already high, and lowers glucagon, a hormone that raises blood sugar. That's why it rarely causes the sugar crashes some older diabetes drugs did.
• A direct effect on fat tissue: researchers think the GIP side acts on fat tissue more directly. How much that adds is still being studied.

None of this burns fat directly. Weight loss on tirzepatide comes from eating less, steadily, over months. That's also why appetite tends to return if you stop. And it's why the lowest starting doses are deliberately too weak to do much yet.

What's the difference between tirzepatide and semaglutide?

The number of receptors is the core difference. Semaglutide activates GLP-1 only. Tirzepatide activates GLP-1 and GIP together.

That difference shows up in results. SURMOUNT-5 was the first trial to test the two drugs directly against each other. After 72 weeks, people on tirzepatide lost about 20% of their starting weight, against about 14% on semaglutide. About 20% of the tirzepatide group lost at least 30% of their weight, against about 7% on semaglutide.

That trial used semaglutide's top dose at the time, 2.4 mg. A higher 7.2 mg Wegovy dose was approved in March 2026. In its own trial, called STEP UP, people on 7.2 mg lost about 18.7% of their weight. That narrows the gap on paper. But no trial has tested tirzepatide against the 7.2 mg dose, so it isn't a real head-to-head answer.

Side effects overlap heavily, since both drugs slow digestion by design. In SURMOUNT-5, about 8% of people on semaglutide stopped because of side effects, against about 6% on tirzepatide.

Whether the extra average result is worth it is personal. Cost, how your body tolerates each drug and how long a track record you want all count. Semaglutide vs. tirzepatide covers the full comparison, with prices. For the mechanism both drugs share, see what is a GLP-1, and how does it work.

What is tirzepatide FDA-approved to treat?

One molecule, two brand names, two sets of approvals. Mounjaro came first, approved in May 2022 for type 2 diabetes. It is now approved for children 10 and older with type 2 diabetes too. In August 2026, Mounjaro also gained approval to lower the risk of heart attack, stroke and heart-related death in adults with type 2 diabetes at high risk.

Zepbound followed in November 2023 for chronic weight management. It's for adults with obesity, or with overweight plus at least one weight-related condition, alongside diet and exercise. In December 2024, Zepbound became the first medicine approved for moderate to severe obstructive sleep apnea in adults with obesity. That approval came from the SURMOUNT-OSA trials.

The labels don't swap. Mounjaro isn't approved for weight loss or sleep apnea, and Zepbound isn't approved for diabetes. It works exactly like Ozempic and Wegovy, where the drug is the same but the label depends on the brand. For Zepbound on its own, see what Zepbound is and how it works.

One gap is worth naming. Zepbound has no heart-risk approval for people with obesity who don't have diabetes. Wegovy does, from its SELECT trial. A tirzepatide trial in that group, called SURMOUNT-MMO, is still running.

Why would a woman in her 40s or 50s without diabetes be prescribed it?

Because Zepbound's approval was never about blood sugar. Eligibility runs on body mass index, or BMI, a ratio of weight to height. You qualify with a BMI of 30 or more, or 27 or more with a weight-related condition. Those conditions include high blood pressure, high cholesterol, sleep apnea and heart disease. Diabetes isn't required.

This comes up more in your 40s and 50s for a reason. Falling, swinging estrogen during perimenopause tends to move fat toward the belly. It also dulls insulin sensitivity, on top of a slowing resting metabolism. Those changes can push a woman over the BMI threshold for the first time in midlife, without anything in her habits changing. Our guide to GLP-1 medications and menopause covers how that overlap plays out.

What does tirzepatide feel like day to day?

The first change most people notice is how much food occupies their head. People call it food noise: the background hum of thinking about the next meal or snack. It tends to quiet down in the first few weeks as the dose climbs. Meals also feel filling sooner, because the stomach empties more slowly.

That early period is also when most side effects cluster: nausea, diarrhea and constipation. They're usually strongest right after a dose increase, then ease as your body adjusts. The dosing schedule lives in the tirzepatide dosage chart. What's common and what needs a call is in tirzepatide side effects.

What are tirzepatide's benefits beyond the scale?

Sleep apnea is the biggest one, because it's an approved use. In the two SURMOUNT-OSA trials, people with obesity and moderate to severe sleep apnea took tirzepatide or placebo, a dummy shot, for a year. About 42% and 50% on tirzepatide reached remission or mild sleep apnea without daytime sleepiness. On placebo, about 16% and 14% did.

Blood pressure and cholesterol shift too, though these aren't separate approvals. In SURMOUNT-1, the main weight trial, systolic blood pressure fell about 7 points on average after 72 weeks. On placebo, it fell about 1 point. Non-HDL cholesterol, the total of the harmful kinds, fell about 8% to 12%, against about 2% on placebo.

Some of that tracks with weight loss itself. None of it replaces a heart-risk approval, which Zepbound doesn't have. For how these changes look over time, see tirzepatide results.

Does the mechanism change once perimenopause is in the picture?

The receptors themselves don't change with reproductive stage. GLP-1 and GIP receptors respond the same way at 28 as at 52. What differs is the body the drug acts on. By perimenopause, muscle has often been shrinking slowly for years, and falling estrogen speeds that up. Resting metabolism shifts with it.

None of that stops tirzepatide from working. But one consequence is worth knowing. Because it lowers how much you eat overall, part of the weight it removes is muscle, not just fat. That's true of fast weight loss in general, and it matters more in midlife. It's a reason to pair the medicine with enough protein and strength training, not a reason to avoid it.